St. Jude Medical, Inc. today announced U.S. Food and Drug Administration (FDA) approval, receipt of European CE Mark clearance and market launch of the QuickSite XL bipolar, left-heart lead to treat heart failure patients. The QuickSite XL lead is used in cardiac resynchronization therapy (CRT) procedures for heart failure patients with average to large size veins. The lead's heightened S-shape is designed to provide stability and allow physicians to successfully position it in bigger veins. St. Jude Medical (http://phx.corporate-ir.net/phoenix.zhtml?c=73836&p=irol-newsreleases#)
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
CoreLink’s 3D Anterior Lumbar Approved by FDA
The implant allows for better imaging by minimizing material density.
Endo Resumes Lawsuit Against FDA Over Bulk Drug Compounding Decree
The company claimed the agency’s handling of bulk compounding laws violates the 2013 Drug Quality and Security Act, treating the laws as non-binding guidance rather than a legal mandate.